One medtech platform,
several development trajectories.
FoRe can progressively open several application fields: medical, clinical research, preclinical, veterinary, NGOs, international markets and specialized detection.
A Strong Technology Base,
Multiple Addressable Markets
FoRe is built on a proprietary technology that combines miniaturization, assay chips, and commercially available reagents. This approach enables a wide range of potential applications in rapid immunological analysis, biomarker quantification, and improved access to selected biological data.
Preciphos follows a progressive development strategy: prioritizing medical and hospital applications first, then expanding into additional markets where portability, low sample-volume requirements, and rapid analysis can create meaningful value.
Medical & clinical:
the strategic core of Preciphos.
The medical and hospital business unit represents Preciphos’s primary development focus. It targets environments where rapid access to selected biological data can contribute to better care pathway organization, particularly in pediatrics, neonatology, critical care, and hospital settings.
FoRe is designed to operate within a controlled hospital framework, in collaboration with hospital medical laboratories and qualified healthcare professionals.
An approach aligned with the growing need for more efficient healthcare systems.
A usage framework to be developed in collaboration with medical, laboratory, and innovation teams.
Environments where delays in accessing information can significantly impact clinical organization and decision-making.
Contexts in which low sample-volume requirements can represent a major clinical advantage.
Beyond the Medical Core:
Additional Growth Pathways
Each business unit presented below represents a potential development pathway, with varying levels of maturity—from areas where traction has already been established to opportunities that remain exploratory.
All of these initiatives follow the same strategic logic: extending the FoRe platform into environments where portability, rapid analysis, and low sample-volume requirements can create meaningful value, depending on the progress of development, validation activities, and strategic partnerships.
Clinical and preclinical research: test, transfer, validate.
FoRe offers strong potential for clinical and preclinical research environments, including biomarker monitoring, client test transfer, and the exploration of new analytical protocols. Preciphos already works with its first active preclinical clients, providing an initial indication of market traction within R&D environments.
(Executive Summary)
In environments where access to laboratory infrastructure is limited, costly, or difficult to organize, a portable platform can create opportunities for healthcare programs, monitoring initiatives, and intervention activities. This approach is intended to be developed through institutional, scientific, and operational collaborations with qualified partners.
The platform’s portability, rapid analysis capabilities, and low-volume testing approach may create opportunities within the veterinary sector, for both livestock and companion animals. Potential applications include rapid diagnostics, biological monitoring, and other specialized uses, subject to further development and validation by Preciphos.
Potential applications for monitoring and field-based veterinary needs.
Beyond medical and biological applications, FoRe’s platform-based approach may offer opportunities in chemical detection, field applications, and specialized monitoring environments. These areas remain exploratory and will be developed according to market opportunities and Preciphos’s strategic priorities.
High-Potential International Markets,
A Progressive Growth Strategy
Preciphos has identified several regions with development potential—including Africa, Eurasia, and other international markets—where faster, portable, and more accessible access to selected diagnostic analyses may address important needs. Future expansion will rely on local partners capable of supporting validation, distribution, and deployment efforts.
These regions represent strategic opportunities and future potential, not an existing global presence.
Explore healthcare needs related to field medicine and available infrastructure.
Identify deployment opportunities through regional networks and strategic partnerships.
Establish distribution, validation, and adaptation capabilities tailored to local contexts.
Structuring the transition
from technology to market.
The development of Preciphos’s business units depends on building partnerships tailored to each target market, including industrialization, distribution, application transfer, use-case validation, scientific collaboration, and international deployment.
Progressive growth,
by market, use case and consumable.
Preciphos’s growth strategy is built on progressive scalability. The analyzers form the installed equipment base, while the proprietary consumables used for each analysis create the potential for recurring revenue streams.
This approach supports expansion by business unit, with growth driven by the number of deployed analyzers, usage volumes, and the markets being addressed.
The recurring revenue model is driven primarily by consumables, not by equipment sales alone.
Would you like to explore a Business Unit
or a partnership with Preciphos?
Preciphos offers qualified discussions with medical, scientific, industrial, institutional, NGO, and investment partners who wish to evaluate the potential of the FoRe platform within their specific environment and area of activity.